Japanification of US drug pricing:Drug price deflation structurally embedded in the US
A consequence of the “new” PBM model is higher US drug prices, initially.One of the consequences of the “new Pharmacy Benefit” (PBM) model in the USwhich has emerged over the last few years, where PBM consolidation has resulted inPBMs gaining pricing power at the expense of Pharma companies, is that new drugprices are initially notably higher in the US. As competition in each therapy classemerges, higher rebates demanded by PBMs in return for continued formularyaccess mean that net drug prices are likely to remain under pressure.
Parallels between US and Japanese drug pricing. In our view, this increases thesimilarities between the US and Japanese drug price structures. In Japan, new drugsare launched at high prices in the expectation that the biennial price cuts will erodethe price of drugs in due course. In the US, the “new” PBM model in effectencourages drug launches at high prices since Pharma companies should expect tohave to provide higher rebates in due course when competition emerges i.e. effectiveprice cuts on potentially an annual basis.
Drug price inflation will likely be more muted and price deflation set to continue.A second consequence of the “new” PBM models is that drug price inflation will likelybe more muted than in the past in the US (enforced by formulary exclusion, not bycorporate discipline). Further, drug price deflation is now becoming structurallyembedded in the US system in competitive therapeutics areas
- 璺�2019楠烇拷9閺堝牐鍌ㄩ弨鎸庢殶閹诡喚鍋ｇ拠鍕剁窗閺€顖氬毉婢堆冪畽婢х偤鏆� 閸╁搫缂撻幎鏇炴倻閸掑棗瀵� 2019-10-18
- 璺�9閺堬拷&3鐎涳絽瀹崇紒蹇旂ス閺佺増宓侀悙纭呯槑閿涳拷9閺堝牊鍨滈崶钘変紣娑撴艾顤冮崝鐘测偓鑹般€冮悳鏉挎礀閺嗭拷 2019-10-18
- 璺�9閺堝牏绮″ù搴㈡殶閹诡喚鍋ｇ拠鍕剁窗6%閻ㄥ嫪淇婇崣锟� 2019-10-18
- 璺�2019楠烇拷9閺堝牅瀵岀憰浣虹病濞村孩鏆熼幑顔惧仯鐠囧嫸绱版稉瀣攽閸樺濮忛柌濠冩杹 閺堫亝娼垫导浣呵旈崣顖涙埂 2019-10-18
- 璺�鐎瑰繗顫囬惍鏃傗敀閿涙DP6.0閸氬海娈戦弨璺ㄧ摜閹跺瀚� 2019-10-18
- 璺�娑旀繃婀€閹村灝婀存禍褎濮囩挧鍕殶閹诡喖鍨庨弸鎰剁窗閹舵洝绁崶鐐舵儰鐡掑绱� 闁库偓閸烆喛绉兼禍搴°偨鏉烇拷 2019-10-18
